Abbott Raises $20 Billion in Debt to Fund Exact Sciences Acquisition

Abbott Laboratories (NYSE: ABT) has successfully priced $20 billion in senior notes to fund its acquisition of cancer diagnostics company Exact Sciences Corporation, according to an 8-K filing with the SEC on February 26, 2026. The massive debt offering represents one of the largest healthcare M&A financings in recent years.

The Deal

The $20 billion debt issuance consists of eight separate tranches with maturities ranging from 2029 to 2066. The offering includes $1 billion in floating rate notes due 2029, alongside fixed-rate notes with yields climbing from 3.7% for the shortest-dated bonds to 5.6% for the 40-year paper due in 2066.

The breakdown shows Abbott's strategic approach to funding: $2.25 billion at 3.7% due 2029, $2.5 billion at 4.0% due 2031, $2.75 billion at 4.3% due 2033, $3.75 billion at 4.65% due 2036, $2 billion at 4.75% due 2038, $3.75 billion at 5.5% due 2056, and $2 billion at 5.6% due 2066. The weighted average interest rate across the fixed-rate portions approaches 4.7%, reflecting current market conditions and Abbott's investment-grade credit profile.

Morgan Stanley, Barclays Capital, Bank of America Securities, and J.P. Morgan Securities are serving as lead underwriters for the transaction, which is expected to close on March 9, 2026, subject to customary closing conditions.

Strategic Rationale

The acquisition of Exact Sciences marks Abbott's most significant move into cancer diagnostics, complementing its existing diagnostics portfolio that generated over $16 billion in revenue last year. Exact Sciences, best known for its Cologuard colorectal cancer screening test, brings proprietary liquid biopsy technology and a robust pipeline of early-detection tests that align with Abbott's strategy of expanding into higher-growth diagnostic markets.

Abbott's decision to fund the entire acquisition through debt rather than a mix of debt and equity preserves shareholder ownership while taking advantage of its strong balance sheet and credit rating. The company's diverse maturity profile—spreading payments across 40 years—provides financial flexibility while managing refinancing risk.

The filing indicates Abbott will use the proceeds not only for the acquisition price but also to refinance certain Exact Sciences debt obligations and cover transaction fees. This comprehensive refinancing suggests Abbott is optimizing the combined entity's capital structure from day one, potentially reducing Exact Sciences' cost of capital through Abbott's superior credit profile.

What to Watch

Investors should monitor several key developments as this transaction progresses. First, the actual acquisition price and terms for Exact Sciences remain undisclosed in this filing, leaving questions about valuation multiples and potential earnout provisions. The size of the debt raise suggests a premium valuation, likely reflecting Exact Sciences' strong growth trajectory and strategic value.

Regulatory approval represents another critical milestone. Given the complementary nature of the businesses—Abbott focuses on broad diagnostics while Exact Sciences specializes in cancer screening—antitrust concerns appear minimal, but the review process could still impact timing.

The integration timeline and synergy targets will be crucial for evaluating the deal's success. Abbott's track record includes successful integrations of St. Jude Medical ($25 billion in 2017) and Alere ($5.3 billion in 2017), but Exact Sciences' specialized oncology focus and direct-to-consumer model present unique integration challenges.

Financially, the $20 billion debt load will significantly increase Abbott's leverage ratios, though the staggered maturities and mix of floating and fixed rates provide some protection against interest rate volatility. The company's ability to maintain its dividend—currently yielding around 2%—while servicing this new debt will be closely watched by income-focused investors.

The transaction also signals intensifying competition in cancer diagnostics, where companies like Illumina (through GRAIL), Guardant Health, and Roche are racing to develop comprehensive screening and monitoring solutions. Abbott's entry with Exact Sciences creates a formidable competitor with the scale and resources to accelerate innovation and market penetration.

Source: Abbott Laboratories Form 8-K filed with the Securities and Exchange Commission on February 26, 2026.

StockCliff Research